COSA Posters: Clinical Research — ASN Events

COSA Posters: Clinical Research — ASN Events

COSA Posters: Clinical Research

Progression free survival vs overall survival: An example from randomised phase III trial with Axitinib (AXIS) in metastatic renal cell carcinoma (#721)

A personalised approach to treating cancer; a cross-sectional review to understand public perception and its capacity to influence clinical outcomes (#722)

Melanoma shared care, a tripartite approach for survival. The patient, their GP and their specialist - A survivorship project. (#724)

Colleen Berryman

A case of delayed methotrexate clearance following administration of a complementary medication containing chlorophyll (#725)

Application of the repertory grid technique to explore medication understanding in patients receiving cancer therapy for breast cancer (#726)

Christine V Carrington

Nicotinamide for skin cancer chemoprevention (#727)

Five-year survival rates for patients (pts) with metastatic melanoma (MM) treated with ipilimumab (IPI) in phase II trials (#728)

Safety of ipilimumab in patients (pts) with untreated, advanced melanoma alive beyond 2 years: Results from a phase III study (#729)

An Australian translational study to evaluate the prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab (Avastin^TM) [ASCENT] (#730)

A randomised controlled trial evaluating Insight, a web-based cognitive rehabilitation programme, in cancer survivors with self-reported cognitive impairment (#731)

Haryana Dhillon

Merkel cell carcinoma in South Western Sydney and Sydney local health districts: a six year retrospective review (#732)

Kirsten J Duggan

Study protocol: optimising men’s uptake of faecal occult blood test screening for bowel cancer: a population based randomised controlled trial (#733)

The diagnostic accuracy of the 7-point checklist to assess pigmented skin lesions in primary care. (#734)

A randomized, phase Ib/II trial of rilotumumab (AMG 102; ril) or ganitumab (AMG 479; gan) with panitumumab (pmab) vs pmab alone in patients with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): primary and biomarker analyses (#735)

To analyse the toxicity and efficacy of concomittant chemotherapy or cetuximab and radiotherapy (chemoradiation) amongst patients of head and neck cancers at the Alan Walker Cancer Centre, Northern Territory from 2010 - 2012 (#736)

Improving the management of chemotherapy toxicities in haematological cancer patients: A phase II randomised controlled trial of the Patient Remote Intervention and Symptom Management System (PRISMS) (#737)

Exploratory landmark analysis of metastatic melanoma patients treated with ipilimumab (#738)

Projecting long term overall survival benefit in metastatic melanoma patients treated with ipilimumab using extrapolation methods (#739)

Perceived barriers to optimal lung cancer care in North Queensland: a qualitative study. (#742)

Shivanshan Pathmanathan

Is there a need for routine cardiac evaluationpre-anthracycline chemotherapy in breast cancer. (#743)

Dagmara M Poprawski

Changes in adiposity, gastro-oesophageal reflux and obesity-related hormones following a 24-week exercise intervention in men with Barrett’s oesophagus (#745)

Marina M Reeves

Vemurafenib and phototoxicity in melanoma (#746)

SQiD – Testing the performance of a Single Question in Delirium case finding for clinical oncology. (#747)

Family connect: a randomised controlled trial to improve psychosocial outcomes for cancer carers. (#748)

It’s all about the numbers! Strategies to Increase Melanoma Trial Participation (#749)

Peri-operative chemotherapy improves relapse-free survival for urothelial carcinoma of the bladder treated by radical cystectomy, but remains under-utilised in an Australian tertiary referral institution (#750)

A retrospective clinical audit comparing neuropathy associated with two different schedules of Oxaliplatin in the treatment of Metastatic Colorectal Carcinoma (#751)

A phase 1b study of trebananib (AMG 386) in combination with pegylated liposomal doxorubicin (PLD) or topotecan (T) in women with recurrent ovarian cancer (#752)

Outlining the protocol for an innovative combined nutrition and physical activity intervention for cancer survivors. (#753)